Harvard Bioscience (HBIO) to Release Quarterly Earnings on Thursday

Harvard Bioscience (NASDAQ:HBIO) is expected to release its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $23.10 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 8:00 AM ET.

Harvard Bioscience Stock Up 1.4%

Shares of NASDAQ HBIO opened at $0.57 on Thursday. Harvard Bioscience has a 12 month low of $0.28 and a 12 month high of $0.95. The company has a market cap of $25.65 million, a price-to-earnings ratio of -0.47 and a beta of 1.51. The business has a fifty day simple moving average of $0.59 and a 200-day simple moving average of $0.57.

Analyst Ratings Changes

Several research analysts have commented on the stock. Zacks Research upgraded shares of Harvard Bioscience to a “hold” rating in a report on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Harvard Bioscience from a “hold” rating to a “buy” rating in a research report on Monday, November 17th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $2.00.

Institutional Investors Weigh In On Harvard Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Corsair Capital Management L.P. boosted its stake in shares of Harvard Bioscience by 1,008.7% during the 4th quarter. Corsair Capital Management L.P. now owns 1,108,692 shares of the medical instruments supplier’s stock valued at $741,000 after buying an additional 1,008,692 shares during the period. Two Sigma Investments LP raised its holdings in shares of Harvard Bioscience by 139.7% during the third quarter. Two Sigma Investments LP now owns 474,157 shares of the medical instruments supplier’s stock worth $208,000 after acquiring an additional 276,372 shares in the last quarter. Strs Ohio acquired a new stake in Harvard Bioscience during the first quarter valued at $117,000. Essex Investment Management Co. LLC purchased a new position in Harvard Bioscience in the fourth quarter valued at about $124,000. Finally, Renaissance Technologies LLC increased its position in Harvard Bioscience by 17.6% in the 4th quarter. Renaissance Technologies LLC now owns 1,021,241 shares of the medical instruments supplier’s stock worth $683,000 after purchasing an additional 152,763 shares during the last quarter. Hedge funds and other institutional investors own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.